Product Overview

CJC-1295 is a laboratory-grade synthetic peptide developed for advanced research involving growth hormone-releasing hormone receptor activity, peptide signalling and molecular communication pathways. Comprising a defined 34-amino acid sequence, the peptide has been structurally modified to improve stability within laboratory research models while maintaining interaction with GHRH receptor systems. Its reproducible molecular characteristics and well-defined peptide structure allow researchers to investigate peptide-receptor interactions, signalling regulation and endocrine pathway behaviour within controlled experimental environments.

Scientific Background

From a molecular science perspective, CJC-1295 is studied because of its interaction with growth hormone-releasing hormone receptor signalling and downstream intracellular communication pathways. Researchers investigate receptor activation, cyclic AMP-associated signalling, transcriptional regulation and peptide stability while comparing its molecular behaviour with naturally occurring GHRH sequences. Its modified structure also supports research into peptide persistence, receptor affinity and signalling efficiency, making it a widely recognised peptide for laboratory investigation involving endocrine regulation and peptide engineering.

Research Applications

CJC-1295 is utilised across laboratory research involving peptide science, receptor biology and endocrine signalling. Researchers commonly apply this peptide to investigate GHRH receptor activity, intracellular signalling pathways, peptide stability, molecular communication and comparative peptide analogue research under controlled laboratory conditions. Additional applications include studies focused on receptor pharmacology, signalling pathway regulation, peptide design and endocrine communication, supporting a broader understanding of peptide-receptor interactions and molecular signalling within advanced scientific research.